Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1

Abstract Introduction Efficacy and safety of the attachment inhibitor fostemsavir + optimized background therapy (OBT) were evaluated through 48 and 96 weeks in the phase 3 BRIGHTE trial in heavily treatment-experienced (HTE) adults failing their current antiretroviral regimen. Here, we report 240-w...

Full description

Bibliographic Details

Published in:	Infectious Diseases and Therapy
Main Authors:	Judith A. Aberg, Bronagh Shepherd, Marcia Wang, Jose V. Madruga, Fernando Mendo Urbina, Christine Katlama, Shannon Schrader, Joseph J. Eron, Princy N. Kumar, Eduardo Sprinz, Margaret Gartland, Shiven Chabria, Andrew Clark, Amy Pierce, Max Lataillade, Allan R. Tenorio
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-09-01
Subjects:	Attachment inhibitor Advanced HIV disease CD4+/CD8+ ratio CD4+ T-cell count Virologic response
Online Access:	https://doi.org/10.1007/s40121-023-00870-6